In the News: November Regulatory and Development Updates
Camargo
DECEMBER 9, 2020
House of Representatives passed the “ Fairness in Orphan Drug Exclusivity Act ” to require proof from biopharma companies introducing improved versions of orphan drugs that they do not expect to recoup R&D costs through US sales in 12 years. GDUFA has changed this picture, at least for complex drug products.
Let's personalize your content